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Current normal tissue complication probability (NTCP) models rely 
heavily on dosimetric parameters that are derived from dose-volume 
histograms (DVHs) which lack the spatial information. These 
parameters assume a homogenous response to radiation and tend to 
ignore any inter or intra-organ variation in radiosensitivity. To address 
these issues in our analysis, we developed an image-based approach 
which utilizes the full 3D dose distribution and does not assume any 
prior knowledge of the OARs. Using image registration, we deformed 
CT scans, anatomic structures, and 3D dose distributions from a 
patient cohort onto the same frame of reference “standard patient”. 
Voxel-based correlations between dose and the complication endpoint 
(trismus) were computed over the entire voxel space to construct a 3D 
correlation map. 
We applied this methodology to a cohort of 110 oropharyngeal cancer 
(OPC) patients treated with IMRT and Chemotherapy at MSKCC 
between 2004 and 2009. The results showed a good agreement 
between the image-based approach and the standard NTCP models. 
Both approaches showed a statistically significant correlation between 
the dose to mastication muscles and trismus. Furthermore, the voxel-
wise 3D correlation map provided additional information and revealed 
regions of high correlation outside the mastication muscle region 
which might suggest the involvement of other organs or tissues at risk. 
However, the clinical implication of these new findings needs further 
investigation in an independent data set and might be related to beam 
arrangement and configuration. 
In addition, we also developed a new metric to estimate the 
geometric uncertainty of the underlying deformable registration which 
we denote as distance discordance (DD). More technical details and a 
few examples will be presented to illustrate the concept of DD and its 
impact on the uncertainty of dose mapping. In summary, this study 
demonstrates the validity of this approach and emphasizes the need 
to consider the full 3D dose distribution in conjunction with DVH 
analysis.  
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Many new treatment units are already on the market that operate 
without a flattening filter (FF) or can be operated in a dedicated 
clinical flattening filter free (FFF) mode, i.e. Tomotherapy, 
Cyberknife, Varian’s True-Beam or ELEKTA’s Agility linacs, 
respectively. The commonly accepted dosimetric benefits of FFF high 
energy photon beams, which range from increased dose rate and dose 
per pulse, to favorable output ratio in-air variation with field size, 
reduced energy variation across the beam, reduced leakage and out-
of-field dose, respectively, imply new dosimetric challenges. These 
are related to beam quality specification, beam calibration, small 
field dosimetry, acceptance testing/commissioning, regular quality 
assurance procedures, and finally treatment plan verification.  
As far as the acquisition of basic relative beam parameters is 
concerned, the commissioning of a FFF treatment delivery unit is not 
very different from a standard linac. However, the increased dose 
rate and the high dose per pulse needs to be considered,since some 
point detectors show a pronounced dose rate dependency (e.g. 
diamond detector, liquid filled ionization chamber), possible 
saturation or reduced collection efficiency.  
The forward peaked dose distribution of FFF beams is fundamentally 
different and makes standard parameters as used for quality control 
of linacs, e.g. homogeneity, field flatness and beam penumbra, not 
always viable. Recently suggestions have been made to overcome this 
issue in clinical dosimetry.  
Small field dosimetry is of special importance since all relevant 
clinical applications of FFF beams are closely related to high precision 
radiotherapy techniques, i.e. stereotactic RT or IMRT, where small 
fields/segments build the basis for treatment delivery. 
Today’s challenge of small beam dosimetry and its link to absorbed 
dose determination in reference geometry is enhanced by unflattened 
beams and dedicated high precision radiotherapy delivery units that 
do not allow to setup the reference conditions, as defined by the IAEA 
TRS 398 or AAPM TG 51 codes of practice. Incorrectly measured beam 
output in small beams can result in systematic uncertainties when 
implementing basic beam data in treatment planning systems(TPS), 
misleading results in acceptance testing/ commissioning of a TPS, and 
finally erroneous patient treatments leading to radiation incidents or 
accidents. Therefore correction factors for a variety of commercially 
available small ion chambers and other radiation detectors are 
currently being investigated in order to extend their use towards small 
beam dosimetry in FFF photon beams. 
The accuracy of dose calculation in TPS represents another dosimetric 
aspect. Several studies demonstrated that inverse planning tools for 
IMRT are able to handle unflattened beams and that the dose 
calculation accuracy of commercial TPS is not impaired when 
removing the FF. 
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The advent of the Flattening Filter Free beams (FFF) available on 
common linacs, is facing the community to the ability of treatment 
planning system to accurately model such beams, and with the 
understanding of which are the best sites and treatments which could 
take advantages from using FFF beams. An overview of the published 
data on dose calculation algorithms accuracy for FFF fields is given. 
The characteristics of the FFF beams are here analyzed to evaluate 
the clinical sites where such beams could take advantage. The main 
characteristics relate to the out-of-field dose (peripheral dose) that 
could lower the organs at risk dose; to the high dose rate, allowing 
shorter treatment time for stereotactical treatments; to the profile 
shape that could be better suitable for small targets or simultaneous 
integrated boost treatments.  
A review of published planning studies presents plan comparisons in 
different sites. Prostate, lung, brain, head and neck plans were 
evaluated for IMRT treatment with different beams (6 and 18 MV, 
flattened and unflattened). Also whole breast plans (with different  
techniques from tangents to IMRT) and esophageal treatment 
(conformal, IMRT, VMAT) where analysed by different groups. Results 
of such studies presenting rather large volumes showed no significant 
difference in plan quality between standard flattened and FFF beams. 
A substantial reduction of MUs and consequently of radiation outside 
the target was evidentiated for most of sites, although the opposite 
could be found for very large (or very elongated) targets, where the 
lower off-axis dose would play an unbeneficial role.  
The lower radiation dose outside the target was also studied on 
anthropomorphic phantom to simulate pediatric IMRT treatments with 
FFF beams in the intracranial regions. The measured dose reduction in 
the periphery (from thyroid to ovaries and testes) was lower of 23 to 
70% relative to the standard flattened beams. 
Particular attention is paid to stereotactical treatments, where the 
high dose rate is the clear and natural benefit in treating with FFF 
beams. Studied sites were early stage lung treatments, liver 
metastases and pelvic/abdominal metastases. 
Examples of lung and brain stereotactical comparisons with and 
without flattening filter are given. 
Conclusions: there are benefits in using FFF beams for some 
treatment site and lesion sizes. The primary benefit is, for high dose 
per fraction treatments, the high dose rate that reduces the beam-on 
time. Other proven benefits are the lower out-of-field and peripheral 
dose, that decrease the critical structures dose and the risk of 
secondary cancer induction. 
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Flattening filter free (FFF) options are now commercially available 
and treatments utilising the higher dose-rates obtained are being 
introduced into clinical use. Removal of the flattening filter results in 
an increase, by a factor of 2-6 times, in the instantaneous dose-rate 
of the x-ray pulse compared to the standard flattened beams. The 
increased dose per pulse, result in an equivalent increase in the 
average dose-rate and a potentially similar reduction in overall 
treatment time. The potential radiobiological factors that result from 
changing the instantaneous dose-rate include potential changes to 
sub-lethal damage repair mechanisms, potential synergistic effects 
and the potential radiobiological effects resulting from changes to the 
overall treatment time. A number of in-vitro studies have been 
undertaken using x-ray beams from linear accelerators designed 
specifically to study the implications of changes in dose-rate of the 
treatment beams resulting from treating with flattening filter free 
beams. These studies have used a variety of experimental 
methodologies to achieve the required instantaneous dose-rates and 
differing ways to ensure dose uniformity over the in-vitro flask. These 
differences in the experimental methodologies have not led to 
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significant differences in results. Three studies have indicated no 
differences in in-vitro cell survival curves between standard and 
flattening filter free irradiations for a range of different cancer cell 
lines. One study suggested differences were present at high doses. In 
this presentation the potential radiobiological implications of 
Flattening Filter Free treatments will be explored and the current 
literature reviewed.  
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FFF beams are now available on medical accelerators for clinical use. 
Without flattening filter, the dose profiles are very different from 
conventional beams. It was necessary to establish new definitions of 
physical parameters such as symmetry, non-uniformity and penumbra. 
Various methods have been published. However, the filtered beams 
are used on the basis of geometric and dosimetric tolerances which 
have now to be redefined for these new FFF beams. 
The tolerances come from a compromise between what is technically 
feasible and what is clinically acceptable. 2% or 2mm are, for 
example, values that are easily translated to the effects on the dose 
profile and clinical irradiations. With FFF beams, amplitude profile 
differences no longer allow the same physical analysis and the impact 
of physical variations, necessarily modulated, are not directly 
understandable. 
It is essential in each radiotherapy center, to drive an investigation on 
geometric and dosimetric tolerances. All different accelerators have 
specific elements that generate and control the photon beams. The 
ionization chamber is at the heart of the device because it is the 
source of information used by the electronics and computer to control 
the beam. Several coils provide manipulation of the electron beam 
before the target. All these elements may vary during voluntary 
adjustments or drifts (age, breakdowns). However, possible variations 
are limited  by the computers. Some interlocks protect from 
unacceptable drift. Thus, the tolerances must at least be evaluated 
within these variations accepted by the manufacturer. 
To obtain tolerances, it is first necessary to assess physically the 
consequences of setting changes on profiles. Then, their impact on 
clinical irradiations have to be analyzed. When a dosimetric variation 
appear unacceptable, the corresponding beam variation help to define 
the tolerable limit. 
Conclusion: The technical evolutions of irradiations leads to 
important modulations with high dose rates for small targets. It is 
essential to establish, in each center, all geometric and dosimetric 
tolerances related to the use of FFF beams. 
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Individualized medicine requires techniques that enable visualisation, 
quantification and time series of disease processes in a non-invasive 
way in individual patients. Medical imaging is intuitively very suitable 
for this purpose. Over the past decades, medical imaging has 
progressed in four distinct ways allowing quantitative imaging: 
innovations in medical devices (hardware), innovations in imaging 
agents, standardisation in imaging protocols, and innovations in 
imaging analysis. By these we have witnessed medical imaging in 
clinical oncology evolving from a primarily diagnostic tool to a 
theragnostic tool by a multitude of techniques involved in the 
treatment and characterisation of tumours and normal organs and 
tissues. Radiation oncology relies heavily on imaging. Computed 
tomography (CT), positron emission tomography (PET), and magnetic 
resonance imaging (MRI) are routinely used, mainly for dose 
calculation (CT) and target volume definition (CT, PET andMRI). 
However, much more can be gained by incorporating functional and 
molecular imaging in the processes of radiation oncology. First, 
imaging can play a major role in identifying interpatient differences 
by assessing the tumour phenotype. An example of this is Radiomics, a 
research field where the imaging data is converted in minable data 
thereby quantifying the tumour phenome. This information cannot 
only be used to select patient specific treatment, but also select for 
further imaging testing,e.g. hypoxia imaging or drug uptake imaging. 
Secondly, imaging plays a role by assessing intra-tumour and intra-
organ heterogeneity. Additional radiation dose must be delivered to 
those parts of the tumour that need it the most, e.g. because of 
increased biologic treatment resistance or reduced therapeutic drug 
uptake, and away from regions inside the lung that are most prone to 
complication. In this presentation we will focus on our work in these 
areas, on extracting more meaningful information from medical 
imaging, in the context of personalized medicine. 
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Magnetic resonance imaging (MRI) offers the potential for better 
tumour localisation, staging and monitoring therapy response 
compared to X-ray CT, due primarily to its inherently superior soft-
tissue contrast resolution. However, problems persist with the 
exclusive use of conventional MRI techniques in therapy planning in 
many body areas, while technical factors (such as image geometric 
distortion and artefacts) also pose problems.  As MRI technology 
continues to evolve, advances such as higher magnetic field strength 
systems, phased array detector coils allowing for fast image 
acquisitions, and multi-transmit technology, are improving the quality 
and robustness of several existing and novel MRI techniques, which 
will impact on radiotherapy planning and follow-up monitoring. 
In addition to conventional high resolution T1 / T2weighted imaging, 
the functional techniques of diffusion weighted imaging (DWI), whole-
body DWI, dynamic contrast enhanced (DCE), dynamic susceptibility 
contrast (DSC) and spectroscopic imaging have all benefited from the 
increased signal arising from high field MRI systems, while emerging 
techniques such as phosphorous spectroscopy and sodium imaging also 
show considerable potential. 
This talk will give a brief overview of MRI before delving into current 
high field MRI technology, explaining how these developments benefit 
both anatomical and functional MR imaging techniques.   
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With the evolution of new detector technologies and dual source CT 
scanners, dual energy CT examinations have become a clinical reality. 
The information of different x-ray spectra can be used to differentiate 
materials based on their specific absorptions. This approach can be 
clinically used to depict and to quantify iodine contrast agents. 
Moreover, postprocessing allows that beside normal appearing CT 
images (120 kVp equivalent) also virtual non-contrast images can be 
reconstructed, which helps to decrease the radiation exposure for 
multiphasic examinations because the pre-contrast scan can be 
omitted. Also reading 80 kVp images can add information because 
vessels or hypervascularized parenchymal lesions usually depict with 
much higher contrast. 
The lecture aims to introduce the basic principle of dual source dual 
energy applications in oncological patients. Moreover, clinical 
examples and results from the literature are presented with a focus 
on abdominal pathologies.  
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